Nigeria - Multiple Indicator Cluster Survey (MICS5) 2016, Fifth round
Reference ID | NGA-NBS-MICS5-2016-v01 |
Year | 2016 - 2017 |
Country | Nigeria |
Producer(s) | National Bureau of Statistics (NBS) - Federal Government of Nigeria (FGN) |
Sponsor(s) | Bill and Melinda Gates Foundation - Bill Gates - Funding partner United Nations Children's Fund - UNICEF - Sponsor Save One Million Lives - SOML - Funding partner United Nations Population Fund - UNFPA - Funding partner World Bank - W |
Metadata | Documentation in PDF Download DDI Download RDF |
Study website |
Created on | Nov 20, 2018 |
Last modified | Nov 20, 2018 |
Page views | 558721 |
Downloads | 73711 |
Times took SP / Fansidar
(MN16)
File: INDIVIDUAL WOMEN MODULE
File: INDIVIDUAL WOMEN MODULE
Overview
Type:
Discrete Format: numeric Width: 2 Decimals: 0 Range: 1-99 | Valid cases: 3425 Invalid: 32751 |
Categories
Value | Category | Cases | |
---|---|---|---|
1 | 1093 | 31.9% | |
2 | 1186 | 34.6% | |
3 | 639 | 18.7% | |
4 | 181 | 5.3% | |
5 | 100 | 2.9% | |
6 | 48 | 1.4% | |
7 | 23 | 0.7% | |
8 | 23 | 0.7% | |
9 | 3 | 0.1% | |
10 | 13 | 0.4% | |
11 | 2 | 0.1% | |
12 | 7 | 0.2% | |
13 | 1 | 0.0% | |
14 | 6 | 0.2% | |
15 | 3 | 0.1% | |
16 | 1 | 0.0% | |
17 | 1 | 0.0% | |
21 | 1 | 0.0% | |
22 | 1 | 0.0% | |
30 | 2 | 0.1% | |
50 | 1 | 0.0% | |
98 | DK | 86 | 2.5% |
99 | Missing | 4 | 0.1% |
Sysmiss | 32751 |
Warning: these figures indicate the number of cases found in the data file. They cannot be interpreted as summary statistics of the population of interest.
Questions and instructions
Check MN14 for medicine taken:
Sulphadoxine Pyrimethamine /Fansidar taken. Continue with MN16.
¨
Sulphadoxine Pyrimethamine /Fansidar taken. Continue with MN16.
¨
During your pregnancy with (name), how many times did you take SP/ Fansidar in total?
Please include all that you obtained either during an antenatal care visit, during a visit to a health facility or from another source?
Sulphadoxine Pyrimethamine /Fansidar not taken. Go to MN17.
Sulphadoxine Pyrimethamine /Fansidar not taken. Go to MN17.
This module is to be administered to all women with a live birth in the 2 years preceding the date of interview. Record name of last-born child from CM13 here _____________________. Use this child’s name in the following questions, where indicated.